Tvardi Therapeutics is trading 5.15% up at $1.02, compared with its October 19 close of $0.97; no clear company-specific news explaining the pre-market rise was found. - The company is scheduled to present at Chardan’s 10th Annual Healthcare Conference on October 20 at 1:30 p.m. ET; the event was announced October 14. - Available information does not establish the conference as the cause of the move. - Biotech-sector pre-market weakness points away from a clear sector explanation.